Key result
Non-bacterial thrombotic endocarditis masquerades as PFO, causing fatal widespread systemic thromboembolism in lung cancer.
Why the study?
Thromboembolic events in cancer patients commonly involve venous and pulmonary circulation, but arterial embolism and cardiogenic origins are rare and require exclusion.
Case Report (n=1)
Answers are grounded in this paper and cite their sources.
Early and correct diagnosis of non-bacterial thrombotic endocarditis in cancer patients is crucial to prevent severe embolic complications and allow for timely anticancer therapy.
Thromboembolic events are frequent in patients with cancer, commonly involving the venous and pulmonary circulation. The arterial system is rarely implicated in embolism and, when involved, a cardiogenic origin should always be excluded. In the present study, a case of a patient who developed multiple embolic events concomitantly with the diagnosis of locally-advanced non-small cell lung cancer with high expression levels of programmed death-ligand 1 (PD-L1) in >50% of tumor cells is reported. A cardiac defect interpreted as a patent foramen ovale required low molecular weight heparin administration. Despite the anti-coagulant therapy, before first-line anticancer treatment with pembrolizumab immunotherapy could be administered due to high PD-L1 expression levels, a new hospitalization was required due to the onset of novel ischemic manifestation. New transthoracic and transesophageal echocardiography revealed a previously misdiagnosed vegetation of the mitral valve that caused systemic embolization. The lack of any sign of infection led to the diagnosis of a non-bacterial thrombotic endocarditis (NBTE), whose embolic sprouting gave rise to the widespread ischemic events. No active anticancer treatment was feasible due to the rapid progression of the disease. NBTE can evolve quickly, eventually preventing any chance of treatment targeting the primary cause, which in the present study was lung cancer. If NBTE can be correctly diagnosed sooner then there may be the potential for anticancer therapy that does not worsen the hypercoagulability state, thus improving cancer-associated survival.
No takes yet. Share an insight, caveat, or question.
Perrone et al. (2020) conducted a case report in Non-bacterial thrombotic endocarditis and non-small cell lung cancer (n=1). Non-bacterial thrombotic endocarditis was evaluated on Clinical outcome (systemic embolization and death). A 63-year-old male with lung cancer developed fatal widespread systemic thromboembolism due to non-bacterial thrombotic endocarditis initially misdiagnosed as a patent foramen ovale.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: